机构:[1]Department of Breast Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China.外科中心乳腺外科中心四川省人民医院四川省肿瘤医院乳腺科[2]Department of Plastic Surgery, Chengdu First People's Hospital, Chengdu, Sichuan 610041, P.R. China.
第一作者机构:[1]Department of Breast Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China.
共同第一作者:
通讯作者:
通讯机构:[*1]Department of Breast Surgery, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55, Section 4, South Renmin Road, Wuhou, Chengdu, Sichuan 610041, P.R. China
推荐引用方式(GB/T 7714):
Xu Jia,Li Xi,Zhang Purong,et al.miR-143-5p suppresses breast cancer progression by targeting the HIF-1α-related GLUT1 pathway.[J].ONCOLOGY LETTERS.2022,23(5):doi:10.3892/ol.2022.13268.
APA:
Xu Jia,Li Xi,Zhang Purong,Luo Jie,Mou Exian&Liu Shiwei.(2022).miR-143-5p suppresses breast cancer progression by targeting the HIF-1α-related GLUT1 pathway..ONCOLOGY LETTERS,23,(5)
MLA:
Xu Jia,et al."miR-143-5p suppresses breast cancer progression by targeting the HIF-1α-related GLUT1 pathway.".ONCOLOGY LETTERS 23..5(2022)